A Deadline is coming up on November 4, 2014 in the lawsuit for investors in Enzymotec Ltd (NASDAQ:ENZY) and Enzymotec Ltd (NASDAQ:ENZY) stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 10/01/2014 -- The Shareholders Foundation announces that a deadline is coming up on November 4, 2014 in the lawsuit filed for investors of Enzymotec Ltd (NASDAQ:ENZY) over alleged violations of Federal Securities Laws by Enzymotec Ltd
Investors with a substantial investment in Enzymotec Ltd (NASDAQ:ENZY) shares between September 27, 2013 and August 4, 2014, should get active before the Deadline that is coming up on November 4, 2014 and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Enzymotec Ltd (NASDAQ:ENZY) securities pursuant and/or traceable to Enzymotec’s Registration Statement and Prospectus issued in connection with the Company’s initial public offering (“IPO”) on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that the Registration Statement and Prospectus allegedly contained materially false and misleading statements and omitted material information, and that defendants misrepresented and/or failed to disclose between September 27, 2013 and August 4, 2014:
- that Enzymotec Ltd’s Chinese business was subject to material and readily identifiable compliance regulations from the Chinese government,
- that Enzymotec Ltd’s baby formula business in China was jeopardized and subject to increased volatility and decreased revenues,
- that Enzymotec Ltd’s joint venture with AarhusKarlshamn AB, which marketed the popular InFat product, was crumbling and subjected the Company to liability and decreased revenues,
- that Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On May 14, 2014, Enzymotec Ltd reported its first quarter 2014 unaudited financial results. Among other things, Enzymotec Ltd said that recent changes in Chinese regulations require infant formula manufacturers to make certain changes to their production chain. Shares of Enzymotec Ltd (NASDAQ:ENZY) declined from $20.23 per share on May 13, 2014, to $12.90 per share on May 16, 2014.
Then on August 5, 2014, Enzymotec Ltd reported its second quarter 2014 financial results. Enzymotec's President and Chief Executive Officer said that "in the second quarter our business experienced operational challenges based on external market dynamics which hindered our financial performance," and that "While we expected these headwinds in the quarter, particularly related to recent regulatory changes in the Chinese infant formula market and weakness in the U.S. and Australian Omega-3 industry”. Shares of Enzymotec Ltd (NASDAQ:ENZY) declined from $14.98 per share on August 4, 2014, to $9.11 per share on August 5, 2014.
On August 29, 2014, Enzymotec Ltd announced new hires to its senior management team.
On September 29, 2014, NASDAQ:ENZY shares closed at $7.00 per share.
Those who purchased shares of Enzymotec Ltd (NASDAQ:ENZY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego